News

Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study with more than 1000 participants with highly chronic TRD.

In a UCB-funded network meta-analysis of 17 trials, bimekizumab ranked first on HiSCR50, HiSCR75, and IHS4-55 among HS drugs at Weeks 12 - 16.

Sachdev explains how VasCog-2-WSO criteria integrate new MRI markers, biomarkers, and unified terminology for vascular dementia.

Meena Bansal, MD, discusses data showing resmetirom lowered Lp(a) and LDL regardless of statin use, plus real-world liver outcomes in nearly 4900 patients.

The 2027 GOLD report recommends a LAMA for group A, defines 6 pre-COPD types, and expands CT, rehabilitation, and cardiovascular guidance for COPD.

TRIUMPH-3 pharmacokinetic data show once-daily trientine tetrahydrochloride achieved exposure comparable to twice-daily dosing for Wilson disease.

Real-world REASON data suggest NCC-Sp, a measure of bioavailable copper, can track treatment response across therapies in unstable Wilson disease.

Jorg Taubel, MD, discusses data showing a single dose of CIDEB siRNA cut liver fat by up to 80% and normalized it in 62% of patients with MASLD.

Behnood Bikdeli, MD, MS, discusses his long-term follow-up to the HI-PRO study, which noted apixaban’s lasting effects on venous thromboembolism.

Ryan Tedford, MD, discusses his analysis of the phase 2 CADENCE trial, highlighting sotatercept’s beneficial effects on both the right and left sides of the heart.

Douglas Dieterich, MD, discusses AZURE-1 data showing brelovitug responses in chronic hepatitis D continued to improve with treatment beyond Week 24.

Kausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.

In the phase 2b IMPACT trial, up to 42.9% of patients with MASH achieved concurrent liver fat, ALT, and stiffness responses on pemvidutide vs 3.3% on placebo.

In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.

Mohammad Alabbas, MD, discusses real-world data comparing liver and cardiovascular outcomes with tirzepatide vs SGLT2 inhibitors in MASLD.

Jörn Schattenberg, MD, discusses ESSENCE data showing semaglutide 2.4 mg improved liver markers in patients with MASH and a BMI below 27 kg/m².

Vijay Shah, MD, discusses phase 2 data showing zalfermin, cagrilintide, and semaglutide improved fibrosis biomarkers in alcohol-related liver disease.

Mohammad Alabbas, MD, discusses a matched real-world comparison of elafibranor and seladelpar in PBC, including 1-year outcomes and limitations for treatment selection.

Todd Villines, MD, discusses the PARAMOUNT trial, which contrasted AI-based CT scan analysis against standard-of-care in patients with suspected CAD.

Gregory Piazza, MD, MS, discusses the results of ROXI-CATH, which illustrated amrecibart’s and cenvacibart’s efficacy in reducing thrombosis events without increasing bleeding.

End-of-study B-Well data show 91% of patients with chronic hepatitis B who achieved functional cure with bepirovirsen maintained it through Week 96.

With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.

Preliminary findings presented at The Liver Meeting 2026 may help inform clinical decisions in adolescents with ALGS transitioning to adult hepatology care.

Raj Vuppalanchi, MD, explains how liver stiffness is becoming a prognostic tool in PBC and PSC, and why context matters when interpreting the number.

IL-33-targeted therapy may reach most patients with COPD regardless of eosinophil count, but questions remain about how drugs act on its 2 forms.

Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).

Post hoc phase 2 data show survodutide improved MASH and fibrosis endpoints across all weight loss categories, including patients losing less than 5%.

Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).